Targeted attack on hidden cancer: new trial for patients with undetectable tumor DNA

This study tests whether adding a special treatment sequence (called sequential cytoreductive intervention) to standard therapy can help people with advanced upper gastrointestinal cancers that have spread but show no detectable tumor DNA in the blood. About 54 adults with cancers like esophageal, stomach, pancreatic, or bile duct cancer will be randomly assigned to receive either standard care alone or standard care plus the extra treatment. The goal is to see if the extra treatment delays cancer progression and improves survival.